Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
The DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index.
Abstract
This report summarizes recommendations from the ACNP Task Force on the conceptualization of remission and its implications for defining recovery, relapse, recurrence, and response for clinical investigators and practicing clinicians. Given the strong implications of remission for better function and a better prognosis, remission is a valid, clinically relevant end point for both practitioners and investigators. Not all depressed patients, however, will reach remission. Response is a less desirable primary outcome in trials because it depends highly on the initial (often single) baseline measure of symptom severity. It is recommended that remission be ascribed after 3 consecutive weeks during which minimal symptom status (absence of both sadness and reduced interest/pleasure along with the presence of fewer than three of the remaining seven DSM-IV-TR diagnostic criterion symptoms) is maintained. Once achieved, remission can only be lost if followed by a relapse. Recovery is ascribed after at least 4 months following the onset of remission, during which a relapse has not occurred. Recovery, once achieved, can only be lost if followed by a recurrence. Day-to-day functioning and quality of life are important secondary end points, but they were not included in the proposed definitions of response, remission, recovery, relapse, or recurrence. These recommendations suggest that symptom ratings that measure all nine criterion symptom domains to define a major depressive episode are p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both reports explicitly requested empirical validations of these now widely used consensus-based definitions.”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Rush et al. (2006)
In the citing paper
“Not only were the specific operationalisations of the duration criteria by Frank et al. (1991) and Rush et al. (2006) not empirically supported”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Rush et al. 2006
In the citing paper
“This definition of relapse is the one most commonly used in clinical studies.39”
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
(1992) · PubMed · Cited by 33,716
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“These reports have relied on a variety of reasonably chosen remission end points at study exit (eg, 17-item Hamilton Rating Scale for Depression p7 or p6 (HRSD17; Hamilton, 1960, 1967) or MontgomeryÄsberg Depression Rating Scale p10 (MADRS; Montgomery and Äsberg, 1979)).”
MethodThe MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Cognitive Therapy for Depression: (675542012-001)
(2012) · PsycEXTRA Dataset · doi:10.1037/e675542012-001 · Cited by 9,663
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Beck, A. T., Steer, R. A., & Brown, G. (2011) · PsycTESTS Dataset · doi:10.1037/t00742-000 · Cited by 7,535
Research works printed but not linked: 2
- American Psychiatric Association (2000b). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (Suppl 4): 1–45.
- Weissman AN (1979). The dysfunctional attitude scale. A validation study. Diss Abst Int 40: 1389B–1390B.
Cited by
Items 301–400 of 697
Hollon, S. D., DeRubeis, R. J., Andrews, P. W., & Thomson, J. A. (2020) · Cognitive Therapy and Research · doi:10.1007/s10608-020-10132-1 · Cited by 26
Krijnen-de Bruin, E., Scholten, W., Muntingh, A., Maarsingh, O., van Meijel, B., van Straten, A., & Batelaan, N. (2022) · PLOS ONE · doi:10.1371/journal.pone.0272200 · Cited by 23
“Although a distinction between relapse and recurrence is described in the literature [15, 16], it appears most studies do not distinguish between the two [17].”
BackgroundTransgenerational effects of maternal depression on affect recognition in children
Kluczniok, D., Attar, C. H., Fydrich, T., Fuehrer, D., Jaite, C., Domes, G., Winter, S., Herpertz, S. C., Brunner, R. M., Boedeker, K., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.051 · Cited by 25
Gao, K., Sweet, J. A., Su, M., & Calabrese, J. R. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.02.013 · Cited by 24
“…from the International Society for Bipolar Disorder (BPD) (Tohen et al., 2009) and the American College of Neuropsychopharmacology Task Force (Rush et al., 2006) for major depressive disorder (MDD) and/or BPD Studies targeting anhedonia would be feasible to perform, given the evidence…”
BackgroundMethodReins, J. A., Ebert, D. D., Lehr, D., Riper, H., Cuijpers, P., & Berking, M. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-318 · Cited by 23
“Response remission, and time to remission Based on the recommendation of Rush (2006), we will use a definition of response/remission that reflects a clinically significant benefit, depending on the specific setting and needs in this trial [68].”
MethodBernstein, I. H., Rush, A. J., Suppes, T. M., Trivedi, M. H., Woo, A., Kyutoku, Y., Crismon, M. L., Dennehy, E. B., & Carmody, T. J. (2009) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.285 · Cited by 27
“This focus is consistent with the aim of measuring remission (absence of the criterion symptoms for a major depressive episode), as suggested by the recent ACNP Task Force Report on remission (Rush et al., 2006c).”
InfluentialSelf-citationJha, M. K., Teer, R., Minhajuddin, A., Greer, T. L., Rush, A. J., & Trivedi, M. H. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s128407 · Cited by 26
“In contrast to the consensus guidelines to evaluate change in depression severity with treatment, 23 there are no similar easy-to-interpret recommendations for measuring or conceptualizing changes in activity impairment.”
Self-citationDesvenlafaxine succinate for major depressive disorder: a critical review of the evidence
Kamath, J., & Handratta, V. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.12.1787 · Cited by 23
Markovic, M., Gallipani, A., Patel, K. H., & Maroney, M. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028016678262 · Cited by 22
Aust, S., Stasch, J., Jentschke, S., Alkan Härtwig, E., Koelsch, S., Heuser, I., & Bajbouj, M. (2014) · Hippocampus · doi:10.1002/hipo.22293 · Cited by 22
Remission in major depression: results from a geriatric primary care population
Azar, A. R., Chopra, M. P., Cho, L. Y., Coakley, E., & Rudolph, J. L. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2485 · Cited by 22
“A recent report by the American College of Neuropsychopharmacology (ACNP) Task Force on response and remission in major depression highlighted two points: (1) the target outcome for treatment of major depression is remission, as opposed to response; and (2) the definitions of remission should include all nine of the D…”
BackgroundAntidepressant medication to prevent depression relapse in primary care: the ANTLER RCT
Duffy, L., Clarke, C. S., Lewis, G., Marston, L., Freemantle, N., Gilbody, S. M., Hunter, R. M., Kendrick, T., Kessler, D. S., King, M., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25690 · Cited by 27
“Single 35/238 (15) 26/240 (11) Separated or divorced 39/238 (16) 33/240 (14) Widowed 18/238 (8) 20/240 (8) Employment status, n/N (%) Employed 140/238 (59) 152/240 (63) Retired 71/238 (30) 68/240 (28) Other 27/238 (11) 20/240 (8) Site, n/N (%) London 101/238 (42) 98/240 (41) Bristol 48/238 (20) 54/240 (23) Southampton…”
Dunlop, B. W., Cha, J., Choi, K. S., Nemeroff, C. B., Craighead, W. E., & Mayberg, H. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01653-w · Cited by 24
“All imaging was carried out using a 3 T Siemens TIM Trio (Siemens Medical Systems, Erlangen, Germany).”
MethodEsketamine versus placebo on time to remission in major depressive disorder with acute suicidality
Fu, D., Zhang, Q., Shi, L., Borentain, S., Guo, S., Mathews, M., Anjo, J., Nash, A. I., O’Hara, M., & Canuso, C. M. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05017-y · Cited by 24
“Patients with MDD who achieve remission exhibit better functioning and an improved prognosis [27], improved health-related [28, 29] and “back-to-normal” [30] quality of life, and improved functional status [31].”
BackgroundQuaranta, S., Dupouey, J., Colle, R., & Verstuyft, C. (2017) · Therapies · doi:10.1016/j.therap.2016.09.018 · Cited by 25
Rush, A. J. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15com09859 · Cited by 22
Self-citationAddressing circadian rhythm disturbances in depressed patients
Lam, R. W. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108092591 · Cited by 26
Health-related quality of life in recurrent major depressive disorder—A 10-year follow-up study
Årdal, G., Lund, A., & Hammar, Å. (2012) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2012.746730 · Cited by 22
Music in depression: Neural correlates of emotional experience in remitted depression
Aust, S., Filip, K., Koelsch, S., Grimm, S., & Bajbouj, M. (2013) · World Journal of Psychiatry · doi:10.5498/wjp.v3.i2.8 · Cited by 21
Dong, L., Zieve, G. G., Gumport, N. B., Armstrong, C. C., Alvarado-Martinez, C. G., Martinez, A., Howlett, S. A., Fine, E., Tran, M., McNamara, M. E., et al. (2022) · Behaviour Research and Therapy · doi:10.1016/j.brat.2022.104167 · Cited by 23
RECURRENCE RISK IN MAJOR DEPRESSION: The Cutting Edge: Recurrence Risk in Major Depression
Patten, S. B. (2013) · Depression and Anxiety · doi:10.1002/da.22030 · Cited by 21
Quelle définition pour la dépression résistante ?
Holtzmann, J., Richieri, R. M., Saba, G., Allaïli, N., Bation, R., Molière, F., Nieto, I., Bellivier, F., Bennabi, D., Bubrovszky, M., et al. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.02.002 · Cited by 32
Treating the depressions with superficial brain stimulation methods
George, M. S., Taylor, J. J., & Short, B. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53497-2.00033-4 · Cited by 22
Evolutionary theory and the treatment of depression: It is all about the squids and the sea bass
Hollon, S. D., Andrews, P. W., Singla, D. R., Maslej, M. M., & Mulsant, B. H. (2021) · Behaviour Research and Therapy · doi:10.1016/j.brat.2021.103849 · Cited by 23
Kiosses, D. N., & Alexopoulos, G. S. (2013) · Psychological Medicine · doi:10.1017/s0033291712000967 · Cited by 21
Defining ‘recovery’ for delirium research: a systematic review
Adamis, D., Devaney, A., Shanahan, E., McCarthy, G. M., & Meagher, D. J. (2014) · Age and Ageing · doi:10.1093/ageing/afu152 · Cited by 21
“schizophrenia and anxiety disorders, and may emphasise temporal or symptomatic elements [5–9].”
BackgroundQuest for Timely Detection and Treatment of Women With Depression
Alexander, J. L. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.9-a.3 · Cited by 24
Sheehan, D. V., Meyers, A. L., Prakash, A., Robinson, M. J., Swindle, R. W., Russell, J. M., & Mallinckrodt, C. H. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802293643 · Cited by 24
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2016) · Focus · doi:10.1176/appi.focus.140202 · Cited by 20
“Response and remission rates are often used to convey the magnitude of treatment benefit; however, these categorical measures are created arbitrarily from underlying continuous rating scale data [50].”
BackgroundMcKibben, L. A., & Dwivedi, Y. (2021) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.05.009 · Cited by 24
“MDD is the most prevalent psychiatric illness and has a particularly heavy financial and societal burden in the United States (3), yet a large percentage of patients do not respond to pharmacologic antidepressant treatment (4).”
BackgroundEletroconvulsoterapia na depressão maior: aspectos atuais
Antunes, P., Rosa, M. A., Belmonte-de-Abreu, P. S., Lobato, M. I. R., & Fleck, M. P. D. A. (2009) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462009000500005 · Cited by 29
Vittengl, J. R., Clark, L. A., Thase, M. E., & Jarrett, R. B. (2015) · Psychotherapy · doi:10.1037/pst0000021 · Cited by 22
“Because MDD is often episodic, treatments may be sequenced (Rush et al., 2006).”
BackgroundSelf-citationKito, S., Miyazi, M., Nakatani, H., Matsuda, Y., Yamazaki, R., Okamoto, T., & Igarashi, Y. (2019) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12066 · Cited by 22
Zimmerman, M., Galione, J. N., Attiullah, N., Friedman, M., Toba, C., Boerescu, D. A., & Ragheb, M. (2011) · Annals of Clinical Psychiatry · doi:10.1177/104012371102300308 · Cited by 20
Impact of Reproductive Status and Age on Response of Depressed Women to Cognitive Therapy
Brandon, A. R., Minhajuddin, A., Thase, M. E., & Jarrett, R. B. (2013) · Journal of Women s Health · doi:10.1089/jwh.2011.3427 · Cited by 25
“In this report, patients are also classified as responders if they achieved at least a 50% reduction in pretreatment HRSD17 scores at study exit and as remitters if they had a final HRSD17 £ 6 at study exit.(38)”
Self-citationShah, L., Chua, J. Y. X., Goh, Y. S., Chee, C. Y. I., Chong, S. C., Mathews, J., Lim, L. H. K., Chan, Y. H., Mörelius, E., & Shorey, S. (2024) · Worldviews on Evidence-Based Nursing · doi:10.1111/wvn.12747 · Cited by 28
Transcranial focused ultrasound targeting the default mode network for the treatment of depression
Schachtner, J. N., Dahill-Fuchel, J. F., Ehrmann, K., Bawiec, C. R., Hollender, P. J., Ornellas, S. B., Konecky, S. D., Achrol, A. S., & Allen, J. J. B. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1451828 · Cited by 23
“After completion of the treatment protocol (i.e., after week 1 or week 3), remission (de fi ned above) and response were assessed, with a decrease of scores below 50% of baseline considered a response as commonly used in previous treatment literature (15, 31).”
Goldberg, J. F. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20190008 · Cited by 20
Snippe, E., Doornbos, B., Schoevers, R. A., Wardenaar, K. J., & Wichers, M. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.04.097 · Cited by 20
Vittengl, J. R., Clark, L. A., Thase, M. E., & Jarrett, R. B. (2014) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0037401 · Cited by 20
“Finally after recovery, maintenance treatments may prevent recurrence and sustain recovery (e.g., Frank et al., 1991; Rush et al., 2006).”
BackgroundInfluentialSelf-citationvan Hees, N. J. M., Giltay, E. J., Geleijnse, J. M., Janssen, N., & van der Does, W. A. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097778 · Cited by 23
“[47].”
Bjørkløf, G. H., Engedal, K., Selbæk, G., Maia, D. B., Borza, T., Benth, J. Š., & Helvik, A. (2017) · Aging & Mental Health · doi:10.1080/13607863.2016.1262817 · Cited by 25
“A score on the MADRS scale of nine points or less is defined as remission in several studies (Borza, Engedal, Bergh, Benth, & Selbæk, 2015; Frank et al., 1991; Heeren, Derksen, van Heycop Ten Ham, & van Gent, 1997; Rush et al., 2006).”
BackgroundCharpeaud, T., Genty, J., Destouches, S., Yrondi, A., Lancrenon, S., Allaïli, N., Bellivier, F., Bennabi, D., Bougerol, T., Camus, V., et al. (2017) · L Encéphale · doi:10.1016/s0013-7006(17)30155-0 · Cited by 23
“[19] Rush AJ, Kraemer HC, Sackeim HA, et al.”
BackgroundInfluentialSawamura, J., Ishigooka, J., & Nishimura, K. (2018) · Health and Quality of Life Outcomes · doi:10.1186/s12955-018-0838-6 · Cited by 20
The olfactory deficits of depressed patients are restored after remission with venlafaxine treatment
Colle, R., Asmar, K. E., Verstuyft, C., Lledo, P., Lazarini, F., Chappell, K., Deflesselle, É., Tayeb, A. E. K. A., Falissard, B., Duron, E., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720003918 · Cited by 29
Schmid, M. T., & Hammar, Å. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.667238 · Cited by 23
Clinically Relevant Findings from STAR*D
Rush, A. J., Kilner, J., Fava, M., Wisniewski, S. R., Warden, D., Nierenberg, A. A., & Trivedi, M. H. (2008) · Psychiatric Annals · doi:10.3928/00485713-20080301-08 · Cited by 21
Self-citationLekman, M., Paddock, S., & McMahon, F. J. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256297 · Cited by 22
“[38,39] Lekman et al.”
Bech, P., Lönn, S. L., & Overø, K. F. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04749blu · Cited by 19
Scherf‐Clavel, M., Hommers, L. G., Wurst, C., Stonawski, S., Deckert, J., Domschke, K., Unterecker, S., & Menke, A. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936509 · Cited by 20
“Week 4 was chosen as the outcome time point as it was suggested that remission may begin during week 4 and therefore an effect in treatment response was expected (Rush et al., 2006).”
MethodResultInfluentialAoun, M. A., Meek, B. P., Clair, L., Wikstrom, S., Prasad, B., & Modirrousta, M. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13488 · Cited by 26
“All of the employed treatment protocols had higher response and remission rates than those reported in literature,(25,56,57) and still outperform conventional pharmacological treatments.(2,3) An explanation for this improved response and remission rates could be the patientscreening criteria used at the clinic when as…”
BackgroundResultBjølseth, T. M., Engedal, K., Benth, J. Š., Dybedal, G. S., Gaarden, T. L., & Tanum, L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.021 · Cited by 19
“Remission was defined as an HRSD17 score of 7 or less (Rush et al., 2006; Zimmerman et al., 2013).”
BackgroundZhang, A., Li, G., Yang, C., Liu, P., Wang, Y., Kang, L., Wang, Y., & Zhang, K. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199456 · Cited by 19
“About 30% of patients with MDD do not respond to standard pharmacotherapy or psychotherapy.(2) They are classified as treatment-resistant depression (TRD).”
BackgroundHough, C. M., Bersani, F. S., Mellon, S. H., Morford, A. E., Lindqvist, D., Reus, V. I., Epel, E. S., & Wolkowitz, O. M. (2020) · Psychological Medicine · doi:10.1017/s0033291720000896 · Cited by 21
“…take longer to occur than response, as it is recommended that treatment trials should be at least 12-weeks when remission is the primary outcome (Rush et al., 2006); and (iii) ‘remission’ is a more difficult target to achieve (Trivedi et al., 2006), requiring meeting pre-defined targets and the…”
BackgroundHarvey, A. G., Dong, L., Lee, J. Y., Gumport, N. B., Hollon, S. D., Rabe‐Hesketh, S., Hein, K., Haman, K., McNamara, M. E., Weaver, C., et al. (2017) · Trials · doi:10.1186/s13063-017-2276-x · Cited by 19
“will be administered along with the Longitudinal Interval Follow-up Evaluation (LIFE) [57] to further ascertain presence/absence of MDD, number and length of mood episodes and remission, response, relapse, recovery, recurrence and time to relapse or recurrence (see Additional file 1 for definitions which are drawn fro…”
MethodSalazar-Fraile, J., Verdú, E. S., Pérez‐Hoyos, S., Tabarés‐Seisdedos, R., & Gómez-Beneyto, M. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00416 · Cited by 21
Zemestani, M., Hosseini, M., Petersen, J. M., & Twohig, M. P. (2022) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2022.08.001 · Cited by 17
Agorastos, A., Sommer, A., Heinig, A., Wiedemann, K., & Demiralay, C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00453 · Cited by 20
“Medication switch and augmentation strategies are then often employed, however with decreasing effectiveness at each successive treatment step (7, 9).”
BackgroundGkesoglou, T., Bargiota, S. I., Iordanidou, E., Vasiliadis, M., Bozikas, V., & Agorastos, A. (2022) · Brain Sciences · doi:10.3390/brainsci12070940 · Cited by 20
“, mood stabilizers or antipsychotics) are often used, while every further step of the therapeutic algorithm shows reduced efficacy [12,26,28].”
BackgroundAschbacher, K., Rivera, L. M., Hornstein, S., Nelson, B. W., Forman‐Hoffman, V. L., & Peiper, N. C. (2023) · Psychosomatic Medicine · doi:10.1097/psy.0000000000001230 · Cited by 22
Schwarz, R., Munkholm, K., Christensen, M. S., Kessing, L. V., & Vinberg, M. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.07.054 · Cited by 17
Bareš, M., Novák, T., Kopeček, M., Stopková, P., Kožený, J., & Höschl, C. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.05.002 · Cited by 17
“Because the relatively short treatment period is probably not sufficient to achieve remission [36] in a substantial proportion of enrolled patients we have presented detailed results (various cut-offs of MADRS reduction) only for responders.”
BackgroundTargeting Treatment-Resistant Depression
Mathys, M. L., & Mitchell, B. G. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011426972 · Cited by 22
“According to the American College of Neuropsychopharmacology Task Force, remission can be clinically defined as the complete absence of sad mood and anhedonia in addition to meeting 3 or fewer of the depression diagnostic criteria (Table 1).(26) In contrast, response is traditionally defined to be a 50% or more reduct…”
MethodKurczewska, E., Ferensztajn-Rochowiak, E., Jasińska-Mikołajczyk, A., Chłopocka-Woźniak, M., & Rybakowski, J. K. (2019) · Pharmacopsychiatry · doi:10.1055/a-0695-9138 · Cited by 17
Han, C., Wang, G., Chan, S. S. M., Kato, T., Ng, C. H., Tan, W., Zhang, L., Feng, Y., & Liu, C.-Y. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s264799 · Cited by 21
A practical approach to the early identification of antidepressant medication non-responders
Li, J.-L., Kuk, A., & Rush, A. (2011) · Psychological Medicine · doi:10.1017/s0033291711001280 · Cited by 21
“…research coordinators collected standard baseline sociodemographic and clinical information, as well as the 16-item Quick Inventory of Depressive Symptomatology – Self-Report (QIDS-SR16) (Kornstein et al. 2002 ; Rush et al. 2003, 2006 ; Trivedi et al. 2004) to measure depressive symptom severity.”
MethodSelf-citationConstantino, M. J., Adams, M. L., Pazzaglia, A. M., Bernecker, S. L., Ravitz, P., & McBride, C. (2013) · Psychotherapy Research · doi:10.1080/10503307.2013.765997 · Cited by 17
“Although response reflects some decrease in symptoms as a function of treatment (often defined as at least 50% reduction), treatment remission, although also variably defined in the literature, reflects a more stringently defined virtual absence of symptomatology (Frank et al., 1991; Rush et al., 2006).”
BackgroundMethodInfluentialBjølseth, T. M., Engedal, K., Benth, J. Š., Bergsholm, P., Dybedal, G. S., Gaarden, T. L., & Tanum, L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.10.013 · Cited by 18
“Remission was defined as an HRSD17 score of 7 or less (Rush et al., 2006; Zimmerman et al., 2013).”
Yrondi, A., Bennabi, D., Haffen, É., Garnier, M., Bellivier, F., Bourgerol, T., Camus, V., d’Amato, T., Doumy, O., Haesebaert, F., et al. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00244 · Cited by 18
The Course of Depressive Symptoms in Older Adults With Comorbid Major Depression and Dysthymia
Hybels, C. F., Pieper, C. F., Blazer, D. G., & Steffens, D. C. (2008) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318162f15f · Cited by 17
Tayeb, A. E. K. A., Colle, R., El‐Asmar, K., Chappell, K., Acquaviva, C., David, D. J. P., Trabado, S., Chanson, P., Fève, B., Becquemont, L., et al. (2021) · Psychological Medicine · doi:10.1017/s003329172100413x · Cited by 18
“…treatment (M0), and 3 months (M3) and 6 months (M6) after the beginning of treatment, which are the recommended durations to assess remission, response and recovery after an antidepressant treatment according to the American College of Neuropsychopharmacology (ACNP) Task Force (Rush et al., 2006).”
MethodInfluentialToward an online cognitive and emotional battery to predict treatment remission in depression
Rekshan, W. R., Gordon, E., Palmer, D., Braund, T. A., & Rush, A. J. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75975 · Cited by 18
Self-citationMontoya, A., Lebrec, J., Keane, K. M., Fregenal, I., Ciudad, A., Moríñigo, Á., Agüera-Ortíz, L., Romera, I., Gilaberte, I., & Zimmerman, M. A. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1067-3 · Cited by 15
“Background Current standards for treatment of major depressive disorder (MDD) recommend that achieving remission should be considered the principal goal [1].”
BackgroundCostemale-Lacoste, J.-F., Colle, R., Martin, S., Asmar, K. E., Loeb, E., Fève, B., Verstuyft, C., Trabado, S., Ferreri, F., Haffen, É., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.062 · Cited by 17
Predicting Neuroimaging Biomarkers for Antidepressant Selection in Early Treatment of Depression
Li, X., Pei, C., Wang, X., Wang, H., Tian, S., Yao, Z., & Lü, Q. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27577 · Cited by 16
“However, due to the heterogeneity of MDD, only 30%–40% of patients can respond or remit after initial antidepressant treatment.(2) Without objective measurements for the selection of antidepressant drugs, most clinicians rely on a “trial-and-error” approach.”
BackgroundTiger, M., Gärde, M., Tateno, A., Matheson, G. J., Sakayori, T., Nogami, T., Moriya, H., Varnäs, K., Arakawa, R., & Okubo, Y. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.07.060 · Cited by 17
Patterns of symptom change in major depression: Classification and clustering of long term courses
Hartmann, A., von Wietersheim, J., Weiß, H., & Zeeck, A. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.03.086 · Cited by 18
Sexual functioning in females with depression in remission receiving escitalopram
Roy, P., Gupta, B., Tripathi, A., Nischal, A., Dalal, P., & Kar, S. K. (2019) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1991_17 · Cited by 18
Viinamäki, H. T., Hintikka, J., Tolmunen, T., Honkalampi, K. M., Haatainen, K. M., & Koivumaa-Honkanen, H. T. (2008) · Nordic Journal of Psychiatry · doi:10.1080/08039480801959281 · Cited by 17
“This should be referred to as subsyndromal symptoms following remission or partial remission (29).”
BackgroundCourtney, D., Watson, P., Chan, B. W. C., BENNETT, K. J., Krause, K. R., Offringa, M., Butcher, N. J., Monga, S., Neprily, K., Zentner, T., et al. (2021) · Depression and Anxiety · doi:10.1002/da.23200 · Cited by 17
“In response to this finding, Frank et al. (1991) set out to operationalize these terms and were later involved in an effort to further specify definitions carried out by the American College of Neuropsychopharmacology Task Force (Rush et al., 2006).”
BackgroundHow much is enough? Considering minimally important change in youth mental health outcomes
Krause, K. R., Hetrick, S. E., Courtney, D. B., Cost, K. T., Butcher, N. J., Offringa, M., Monga, S., Henderson, J., & Szatmari, P. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00338-8 · Cited by 15
Positioning rTMS Within a Sequential Treatment Algorithm of Depression
Kaster, T. S., & Blumberger, D. M. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240604 · Cited by 16
Bombardier, C. H., Fann, J. R., Wilson, C. S., Heinemann, A. W., Richards, J. S., Warren, A. M., Brooks, L., Warms, C. A., Temkin, N. R., & Tate, D. G. (2013) · Journal of Spinal Cord Medicine · doi:10.1179/2045772313y.0000000138 · Cited by 17
Deep Brain Stimulation for Treatment-Resistant Depression
Kaur, N., Chou, T., Corse, A. K., Arulpragasam, A. R., Deckersbach, T., & Evans, K. C. (2013) · Psychiatric Annals · doi:10.3928/00485713-20130806-04 · Cited by 16
Watanabe, M., Umezaki, Y., Miura, A., Shinohara, Y., Yoshikawa, T., Sakuma, T., Shitano, C., Katagiri, A., Takenoshita, M., Toriihara, A., et al. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0422-0 · Cited by 15
Recovery and subsequent recurrence in patients with recurrent major depressive disorder
Dunlop, B. W., Holland, P., Bao, W., Ninan, P. T., & Keller, M. B. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.03.002 · Cited by 15
“Two recovery duration criteria (8 weeks [56 days] and 4 months [120 days]) were employed based on previously used duration definitions (Frank et al., 1991; Keller et al., 1983; Furukawa et al., 2008) and those recommended by the ACNP Task Force (Rush et al., 2006).”
BackgroundMethodSelf-citationPsychiatric Disorders - Worldwide Advances
Uehara, T. (2011) · InTech eBooks · doi:10.5772/1289 · Cited by 16
Developing Cognitive Behavioral Therapy to Prevent Depressive Relapse in Youth
Kennard, B. D., Stewart, S. M., Hughes, J. L., Jarrett, R. B., & Emslie, G. J. (2008) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2008.02.006 · Cited by 18
“Typically the treatment of depression can be divided into three phases: acute (treatment that results in clinical response and remission of symptoms), continuation (treatment to prevent relapse of symptoms of the index episode), and maintenance (treatment to prevent new episodes, or recurrences; Frank et al., 1991; Ku…”
Metabolomic profiles of 38 acylcarnitines in major depressive episodes before and after treatment
Tayeb, A. E. K. A., Colle, R., Chappell, K., El‐Asmar, K., Acquaviva, C., David, D. J. P., Trabado, S., Chanson, P., Fève, B., Becquemont, L., et al. (2023) · Psychological Medicine · doi:10.1017/s003329172300140x · Cited by 20
Berk, M. S., Gallop, R., Asarnow, J. R., Adrian, M. C., Hughes, J. L., & McCauley, E. (2024) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2024.01.012 · Cited by 18
Operationalism and realism in psychometrics
Vessonen, E. (2019) · Philosophy Compass · doi:10.1111/phc3.12624 · Cited by 22
Thom, R. P., Palumbo, M. L., Thompson, C., McDougle, C. J., & Ravichandran, C. T. (2021) · Brain Sciences · doi:10.3390/brainsci11091216 · Cited by 13
“Patients were classified as having attained remission and recovery if at least three weeks or four months, respectively, of minimal depressive symptoms [26] had been attained at the time of the most recent psychiatry follow-up visit.”
Yu, R., Zhang, Z., Chen, R.-S., Wang, X., Li, X., Dai, L., & Li, Z. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.027 · Cited by 18
Janssen, N. P., Lucassen, P. L., Huibers, M. J. H., Ekers, D., Broekman, T. G., Bosmans, J. E., van Marwijk, H., Spijker, J., Voshaar, R. C. O., & Hendriks, G. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000531201 · Cited by 23
Lin, C., Chou, L., Chen, M., & Chen, C. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.022 · Cited by 16
Measurement-Based Care in the Treatment of Clinical Depression
Morris, D. W., Toups, M. S. P., & Trivedi, M. H. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.4.428 · Cited by 15
Self-citationPrediction of Response to Antidepressants: Is Quantitative EEG (QEEG) an Alternative?
Iosifescu, D. V. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00063.x · Cited by 14
“Although partial or inadequate response to antidepressant treatment is common in major depressive disorder (MDD), only about 30–40% of the patients who receive adequate pharmacotherapy will achieve full remission (absence or near absence of symptoms) [1].”
BackgroundHaley, C. L., Kennard, B. D., Morris, D. W., Bernstein, I. H., Carmody, T. J., Emslie, G. J., Mayes, T. L., & Rush, A. J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s400591 · Cited by 19
“includes ratings of both symptoms and function, which can create a potential confound in measuring symptom remission.(24) Thus, the CDRS-R may be less sensitive to detecting symptom remission since the rated functional difficulties may have been present prior to MDE onset or, as in adults, they may take longer to reso…”
BackgroundSelf-citationWhat we got wrong about depression and its treatment
Hollon, S. D. (2024) · Behaviour Research and Therapy · doi:10.1016/j.brat.2024.104599 · Cited by 16
Grützner, T. M., Sharma, A., Listunova, L., Bartolovic, M., Weisbrod, M., & Roesch-Ely, D. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.11.047 · Cited by 19
Metadata
- Authors
- Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., Regier, D. A., Rosenbaum, J. F., Ray, O., & Schatzberg, A. F.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Stanford Medicine (US)
- University of Pittsburgh (US)
- Emory University (US)
- University of Arizona (US)
- American Psychiatric Association (US)
- Harvard University (US)
- Vanderbilt University (US)
- Corresponding author
- Rush, A John
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2006-06-21
- Volume
- 31
- Issue
- 9
- Pages
- 1841-1853
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2039979496
- Cited by
- 707
- References
- 132
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 29 · 2023: 58 · 2022: 30 · 2021: 47 · 2020: 30 · 2019: 47 · 2018: 35 · 2017: 30 · 2016: 41 · 2015: 33 · 2014: 32 · 2013: 36 · 2012: 35
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Mental Health Research Topics
- Keywords
- major depressive disorder, remission, response, recovery, relapse, recurrence, end points, symptom rating scales, DSM-IV-TR diagnostic criteria, clinical trial results, quality of life
- MeSH terms
- Clinical Trials as Topic, Major Depressive Disorder, Humans, Recurrence, Research Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.